Table 1 Differences in the studied parameters between the non-PM and PM groups.

Eyes, n

19

99

Age at baseline, years

63.4 ± 9.6

66.9 ± 9.8

0.09^†

AL at baseline, mm

28.53 ± 0.94

29.49 ± 1.73

0.03*

Male sex, n (%)

1 (5)

26 (26)

0.046^†*

LogMAR BCVA

Baseline

0.29 ± 0.34

0.52 ± 0.39

0.02*

1-year

0.12 ± 0.22

0.37 ± 0.40

0.01*

2-year

0.20 ± 0.33

0.40 ± 0.43

0.02*

3-year

0.28 ± 0.38

0.41 ± 0.42

0.10

4-year

0.28 ± 0.36

0.46 ± 0.41

0.07

MNV location at baseline (extrafoveal/juxtafoveal/subfoveal), n

6/0/13

23/20/56

0.67^‡

MNV size at baseline, mm²

0.42 ± 0.49

0.57 ± 0.65

0.52

CRT at baseline, μm

288.9 ± 107.3

291.1 ± 153.5

0.82

CCT at baseline, μm

74.2 ± 36.7

57.9 ± 22.3

0.06

Number of injections, n

1st year (0–1 year)

2. 9 ± 1.3

1.9 ± 1.2

0.002*

2nd year (1–2 years)

0.9 ± 1.1

0.5 ± 1.0

0.02*

3rd year (2–3 years)

0.6 ± 1.0

0.2 ± 0.7

0.002*

4th year (3–4 years)

0.2 ± 0.5

0.2 ± 0.6

0.97

Total (0–4 years)

4.6 ± 2.6

2.9 ± 2.6

0.001*

Ratio of IVR against the total number of injections

0.70 ± 0.45

0.59 ± 0.45

0.18

No additional treatment, n (%)

3 (16)

35 (35)

0.095^†

ERM, n (%)

Baseline

2 (11)

20 (20)

0.32^†

4-year

3 (16)

31 (31)

0.17^†

LMH, n (%)

Baseline

0 (0)

0 (0)

–

4-year

0 (0)

3 (3)

0.44^†

Lens status, n (phakia/pseudophakia/aphakia)

Baseline

14/5/0

67/31/1

0.82^‡

4-year

11/8/0

43/55/1

0.48^‡